DISA Limited Announces Completion of Strategic Transactions in Advance Digital Healthcare Pte. Ltd.
Singapore, 8 June 2026 – DISA Limited (the Company, together with its subsidiaries, the Group) has announced the completion of two significant transactions involving Advance Digital Healthcare Pte. Ltd. (ADH). These transactions, previously disclosed on 23 March 2026, are set to reshape the Company’s investment position in ADH and may have material implications for shareholders.
Key Points of the Announcement
- Disposal of Shares in ADH: The Company has completed the sale of 2,274,000 shares in ADH, representing 7.580% of ADH’s total issued and paid-up capital, to Mr. Meng for a consideration of S\$1,000,000.
- Subscription of New Shares in ADH: Concurrently, Mr. Meng has subscribed for 1,726,000 newly issued shares in ADH (5.753% of ADH’s total issued and paid-up capital) for a subscription consideration of S\$1,000,000.
- Post-Transaction Shareholding: Following the completion of both the disposal and subscription, DISA Limited now holds 87.392% and Mr. Meng holds 12.608% of the issued share capital of ADH.
- Board Appointment: Mr. Meng will also be appointed as a director of ADH, potentially bringing new direction and oversight to the company.
Important Considerations for Shareholders
- Strategic Realignment: The transactions represent a strategic realignment of DISA Limited’s interest in ADH. The sale and subsequent re-issue of shares effectively bring in new capital while maintaining a dominant controlling stake.
- Potential Share Price Impact: The injection of S\$2 million in total (S\$1 million from the sale and S\$1 million from the new subscription) may strengthen ADH’s capital base, potentially supporting further growth or financial stability. The appointment of Mr. Meng as a director introduces new leadership, which could affect future strategy and valuation of ADH.
- Change in Shareholding Structure: Shareholders should note the precise post-transaction shareholdings, as any further dilution or equity changes may impact the Group’s earnings and long-term value.
- Regulatory and Sponsor Oversight: The transaction has been reviewed by SAC Capital Private Limited, the sponsor. However, it has not been examined or approved by the Singapore Exchange Securities Trading Limited (SGX-ST), and the SGX-ST assumes no responsibility for the contents.
Conclusion
These transactions are potentially price-sensitive due to their impact on DISA Limited’s financial position, control over ADH, and the introduction of new directorship. Investors are advised to monitor future disclosures and developments regarding ADH, as these may further influence the Company’s prospects and valuations.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult their financial advisor before making any investment decisions. The information provided is based on official company announcements and may be subject to change.
迪莎有限公司完成对先进数字医疗私人有限公司股份的处置与认购——投资者重要信息
新加坡，2026年6月8日——迪莎有限公司（下称“公司”，连同其子公司，下称“集团”）宣布已完成两项关于先进数字医疗私人有限公司（下称“ADH”）的重大交易。这两项交易于2026年3月23日首次披露，预计将重塑公司在ADH的投资地位，对股东具有重要意义。
公告要点
- 处置ADH股份：公司已完成向孟先生出售2,274,000股ADH股份（占ADH总已发行及缴足股本的7.580%），对价为100万新元。
- ADH新股份认购：同时，孟先生以100万新元认购了ADH新发行的1,726,000股股份（占ADH总已发行及缴足股本的5.753%）。
- 交易后持股结构：交易完成后，公司持有ADH 87.392%股权，孟先生持有12.608%股权。
- 董事会任命：孟先生将被任命为ADH董事，为公司管理层带来新视角和指导。
股东须知的重要事项
- 战略调整：本次交易为公司在ADH的持股结构进行了战略性调整。股份的出售及重新发行为公司带来新的资本，同时保持了控股地位。
- 股价潜在影响：两项交易共计注入200万新元（出售及认购各100万新元），有望增强ADH的资本基础，支持其未来发展或财务稳定。孟先生的董事任命亦可能影响公司未来战略及估值。
- 股权结构变化：投资者需关注交易后具体持股比例，未来如有进一步稀释或股本变动，可能影响集团盈利和长期价值。
- 合规与监管：本次交易已由SAC Capital Private Limited审阅，但尚未获得新加坡交易所（SGX-ST）的审查或批准，SGX-ST对本公告内容不承担任何责任。
总结
本次交易对迪莎有限公司的财务状况、对ADH的控制力以及管理层变动具有潜在价格敏感性。建议投资者密切关注公司后续公告及ADH发展动态，以评估对公司业绩和估值的进一步影响。
免责声明：本文仅供参考，不构成投资建议。投资者应自行进行尽职调查，并在作出投资决策前咨询专业理财顾问。本文信息基于公司官方公告，可能会有变更。
